BN 82451

Drug Profile

BN 82451

Alternative Names: BN-82451B; BN82451

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsen
  • Class Amines; Neuroprotectants; Phenols; Small molecules; Thiazoles
  • Mechanism of Action Lipid peroxidation inhibitors; Monoamine oxidase B inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Discontinued Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

  • 31 May 2016 Ipsen completes enrolment in its phase II trial for Huntington's disease in Germany (NCT02231580)
  • 01 Sep 2014 Phase-II clinical trials in Huntington's disease in Germany (PO)
  • 26 Nov 2013 Phase-II clinical trials in Huntington's disease in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top